

MiMedX Group Inc.

Fact Sheet

M D X G

S Y M B O L

OTC

MIMEDX

QUICK REFERENCE

MiMedx Group, Inc.

Trading Symbol: MDXG

Outstanding Shares: **111,034,873**

Website: **www.MIMEDX.com**

BUSINESS SUMMARY

MiMedx® is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to provide physicians with products and tissues to help the body heal itself. We process human placental tissue utilizing our proprietary PURION® process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. Since our founding, research and development has been the cornerstone of our organization. As a result, we have grown to be the leader in placental based products with over 40 scientific and clinical publications, multiple published Randomized Controlled Trials (RCTs), and 30 ongoing clinical studies. MiMedx has over 45 placental tissue issued and allowed patents on our products and technologies, with over 90 pending applications. We have continued to demonstrate this leadership by publishing a Primer to educate the medical community on the regenerative aspects of amniotic membrane allografts. MiMedx has supplied over 1.5 million placental tissue-based allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

HEALING GIFTS

The MiMedx® Placenta Donation Program, Give the Gift of Healing, provides an opportunity for mothers delivering full-term Caesarean section births to donate their placenta (often referred to as “afterbirth”) for medical uses. The placenta is normally discarded as medical waste. However, through donation, the family can provide a priceless gift of healing to those in need. This generous gift creates a personal legacy for the family and newborn knowing that they are helping individuals who require treatment for their difficult-to-heal wounds such as diabetic foot ulcers, venous leg ulcers and burns, or soft tissue injuries, and even those undergoing spine, eye and oral surgeries.

PRODUCTS

- AmnioFix
- EpiFix
- EpiBurn
- AmniCord
- EpiCord
- AmnioFill

CONTACT INFORMATION

US Headquarters
1775 West Oak Commons Ct. NE
Marietta, GA 30062

Investor Relations Contact
Andrew Barwicki
516-662-9461/andrew@barwicki.com

MiMedx will hold its 2018 annual meeting of shareholders (the "Annual Meeting") on Monday, June 17, 2019, at 9:00 a.m. local time, at the Marietta Conference Center (Hilton Atlanta/Marietta) at 500 Powder Springs St., Marietta, GA 30064.

The Board has fixed the close of business on May 9, 2019 as the record date for shareholders who will be entitled to vote at the Annual Meeting.

Recent Press Releases (*Headlines and Excerpts*)

MiMedx Files Definitive Proxy Materials and Mails Letter to Shareholders

Urges Shareholders to Vote "FOR" All the Board's Qualified Nominees on the BLUE Proxy Card

June 3, 2019 -- MiMedx Group, Inc. announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission ("SEC") in connection with its upcoming 2018 annual meeting of shareholders ("Annual Meeting") scheduled to be held on June 17, 2019 at 9:00 a.m. local time, at the Marietta Conference Center (Hilton Atlanta/Marietta) at 500 Powder Springs St., Marietta, GA 30064.

Shareholders as of the close of business on May 9, 2019 are entitled to notice of, and to vote at, the Annual Meeting. For more information regarding the Annual Meeting, please visit www.VoteBlueforMiMedx.com.

MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point

Six New Directors to Join the Board

Dr. M. Kathleen Behrens Wilsey to be Named Chairwoman of the Board

Refreshment Comes After Audit Committee Concludes its Independent Investigation and Engages a New Independent Registered Accounting Firm

May 30, 2019 -- MiMedx Group, Inc. announced that the Company's board of directors (the "Board") has adopted a comprehensive plan to refresh the composition of the Board. The plan was developed by the Board in cooperation with one of the Company's largest shareholders, Prescience Point Capital Management LLC ("Prescience Point"), and follows the completion of the Audit Committee's independent investigation into alleged wrongdoing by the prior senior management team and the engagement of BDO USA, LLP as the Company's new independent registered public accounting firm.

MiMedx Announces BDO as the Company's New Independent Registered Public Accounting Firm Marks Important Step in Advancement of Company's Financial Restatement Process

May 28, 2019 -- MiMedx Group, Inc. announced that the Audit Committee of the Company's Board of Directors approved the engagement of BDO USA, LLP ("BDO") as the Company's new independent registered public accounting firm. BDO delivers assurance and tax advisory services to clients throughout the country and around the globe, and is the 5th largest firm in the world serving publicly traded domestic and international clients.

MiMedx Appoints Timothy R. Wright as Chief Executive Officer

Healthcare Industry Veteran to Lead Next Phase of MiMedx

May 9, 2019 -- MiMedx Group, Inc. announced that its Board of Directors has appointed Timothy R. Wright as Chief Executive Officer, effective May 13, 2019. Mr. Wright succeeds David Coles, who has served as Interim Chief Executive Officer since July 2018.

Mr. Wright is a proven executive and healthcare industry veteran with more than 30 years of experience in the pharmaceutical, biotech and medical devices industries. He brings to MiMedx a track record of results-oriented leadership and business growth.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

MiMedx Group, Inc.

Trading Symbol: MDXG

WWW.MIMEDX.COM

Barwicki Investor Relations * 30 Wall Street, 8 FL * New York, NY 10005

Deliver to: